Allergic rhinitis has been conservatively estimated to affect 35 million Americans, with an annual US expenditure ofmore than $2 billionfor treatment. Immunotherapy is generally administered to patients with allergic rhinitis when avoidance is impossible or impractical, when pharmacotherapy provides insufficient relief, and/or symptoms span more than one season. Immunotherapy based on quantified testing (e.g., dilutional intradermal testing {SET] or in vitro methods (RAST, ELISA]) allows administration ofantigens in a manner that achieves therapeutic antigen doses more rapidly, yet more safely than immunotherapy administered through a schedule that mixes all antigens at the same concentration and advances on an empirical basis. Sixty patients who received at least one year of quantified testing-based immunotherapy were evaluated using a quality of life questionnaire and individual interviews. Changes in physical, social and emotional well-being were determined. Also investigated were changes in productivity and medication usage. The majority ofpatients noted significant improvement in all areas withinfour to six months ofinitiating immunotherapy, and an overwhelming majority felt that such treatment represented a worthwhile investment oftheir time and money.
Introduction
Seasonal allergic rhinitis has been conservatively estimated to affect 35 million Americans. I Other sources estimate the prevalence of allergic rhinitis to be approximately 24% of the US population." It is estimated that the annual US expenditure for allergic rhinitis treatment is ' When these diseases are also included, the expenditure rises to an estimated $10 billion annually. The average annual per-patient cost for perennial allergic rhinitis is $460, and for seasonal rhinitis, $280. 1 Treatment options for allergic rhinitis include environmental control, pharmacotherapy and immunotherapy. The initial and most important treatment modality is environmental control.' Pharmacotherapy includes decongestants, antihistamines, mast cell stabilizers and steroids.r" The final option in the treatment of allergic rhinitis is immunotherapy. When allergic symptoms are clearly significant to the patient and allergen avoidance fails or is impractical, immunotherapy should be considered. Additionally, when pharmacotherapy is not successful, not used regularly, not well tolerated, or has potential toxicity, immunotherapy is useful. Finally, immunotherapy should only be used when sensitivity to specific allergens relevant to the patient's exposure history can be established.'
Immunotherapy can be administered using an empiric scheme of vial preparation and dosage escalation, or may be based on the results of quantitative testing methods such as skin endpoint titration (SET) and in vitro tests, RAST (radioallergosorbent test) and ELISA (enzyme-linked immunosorbent assay)." Such immunotherapy is initiated at the endpoint concentration or RAST-I level (after a confirmatory vial skin test) for each positive antigen. The dose is then increased until reaching a maintenance dose (symptom-relieving or maximally tolerated). Maintenance therapy is continued for three to five years to provide longterm allergy relief."
In general, many studies support the benefits of allergy immunotherapy for well-defined seasonal allergy to a limited number of allergens. Double-blind trials documenting immunotherapy with multiple allergens have With these methods, the speed with which patients can reach a point of symptomatic relief is delayed because many allergens are initiated at dilutions well below their threshold of sensitivity. Immunotherapy based on quantitative testing (SET) was shown to be effective in one study." However, successful outcomes were determined only by improvement in symptoms and a decrease in total IgE. RASTbased immunotherapy has not been similarly evaluated. A quality oflife analysis for patients receiving immunotherapy based on quantitative testing has not been reported. The SF-36 Health Status Questionnaire has previously been utilized to evaluate the effect ofallergic rhinitis on the quality of life. I I This health survey form evaluates quality oflife issues using nine subsets: physical functioning, social functioning, role limitations attributed to physical and emotional problems, mental health, energy/fatigue, pain, general perception of health, and change of health. We used ideas from this questionnaire and knowledge of impairments imposed by allergic rhinitis described in other studies'? to devise our own quality oflife questionnaire (Table) . Utilizing our questionnaire, we set out to perform an analysis of changes in quality of life following allergy immunotherapy based on quantitative testing methods.
Materials and Methods
Sixty patients receiving allergy immunotherapy for allergic rhinitis under the care of one author (RLM) were evaluated. These patients were not improved or inadequately controlled by avoidance and pharmacotherapy. All patients had documented IgE-mediated allergy to seasonal and/or perennial allergens by quantitative testing. The only other inclusion criterion was that all patients must have undergone immunotherapy for one year or more. These patients were interviewed using our questionnaire, and chart reviews were performed. All 60 patients had RAST testing to quantify allergy sensitivity. In addition, 13 of the patients had been tested by SET to quantify allergen sensitivity to second-tier molds and other antigens. Thirty-six patients were men, ages 27-70, and 23 were women, ages 29-72.
Patients were first asked to rate their nasal symptoms, currently and before beginning immunotherapy, on a scale ofO=none, l=mild, 2=moderate, and 3=severe. Nasal symptoms addressed included sneezing, pruritis, rhinorrhea, congestion and impaired smell or taste. As some of these patients had a balance disorder, patients were also asked to rate balance disturbance/dizziness when applicable. The number of sinus or upper respiratory infections in a l2-month period were compared, currently and before immunotherapy.
Patients were asked to judge whether their general health was much better, somewhat better, about the same, somewhat worse, or much worse since starting allergy injections. Patients were questioned about the effect of FELL,MABRY,MABRY immunotherapy on exercise tolerance, tolerance of outdoor activities, participation in social activities, and energy level for everyday activities.
Each patient was asked whether immunotherapy had an effect on their productivity at work. If productivity was increased, we attempted to determine whether this was because of fewer allergy symptoms, fewer infections, or fewer side effects from prior medications. Additionally, we evaluated whether immunotherapy decreased the number of work days missed. Patients were asked if allergy shots had decreased their number of physician visits to treat either severe allergy symptoms or infections. The amount of medications taken currently and before immunotherapy was compared.
Finally, patients were asked whether they felt allergy injections had been a worthwhile investment of their time and money. Chart reviews were done to further validate the patients' answers on the questionnaire, to qualify and quanti fy their allergen sensi tivity, and address the progress of immunotherapy.
Results
A finding of significant improvement in nasal symptoms was based on at least aone-point improvement in two _~Yl:' lp~~ms plus the patient's self-e",aluation that the nasal symptoms were significantly better. Fifty-five of the 60 patients (92%) reported a significant improvement in symptoms. To evaluate the effect of immunotherapy on infection rate, we considered three sinus or upper respiratory infections per year to be significant. Sixteen of the patients had fewer than three infections per year before beginning allergy injections. Of the 44 patients with three or more infections per year pre-immunotherapy, 40 (91 %) stated their infection rate had decreased by 50% or more since starting the allergy injections. Sixty-two percent (37/ 60) of those interviewed said their general health was much better since beginning immunotherapy. Eighteen people felt they were somewhat better, five stated they were about the same, and none reported being worse.
Twenty-three of the 60 patients (38%) reported an increase in exercise tolerance with immunotherapy. When questioned about outdoor activities such as gardening or sports, only 34 of those interviewed stated they did any outdoor activities regularly. Twenty-five of these (74%) were able to perform these activities more easily since starting immunotherapy. Social activities frequently are affected by one's well-being. Sixty-three percent of those interviewed stated they had an improvement in their social lives since starting the allergy shots. Along this same line, 55% (33/60) had an increased energy level. Choice" products at 602-946-7221 or 800-758-8185.
FELL, MABRY,MABRY treatment of severe allergy symptoms or infections. These people, on average, had a decrease in these extra visits by 3.8/six months after starting allergy immunotherapy. Evaluating medication usage was somewhat more difficult. Patients were rarely able to recall the precise amount of each medication they took for their allergies, but most patients were able to give a rough estimate. Additionally, chart reviews helped in determining medication types, dosages, and number of prescriptions. Most patients had tried several different anti-allergy medications. Comparing the total medication intake (excluding antibiotics) before and after achieving maintenance immunotherapy, 63% of the patients were able to decrease the amount of each medication taken. It is important to note, however, that only a few patients were able to completely stop all medications. The majority still needed antihistamines, cromolyn or decongestants for symptom exacerbations. Twenty-one patients used topical nasal steroids regularly before beginning immunotherapy. The effects of immunotherapy allowed 18 (86%) of these patients to discontinue the use of nasal steroids.
Considering the total antibiotic intake, as with the infection rate, the need for three or more courses of antibiotics per year was considered significant. Of the 44 people with a history of three or more infections per year, eight took When people are ill, performance in the workplace is often affected. Fifty-six people in our survey were employed. Thirty-three of them stated that their allergies or infections had caused them to be less productive at work. The other 23 stated that they never let their allergies or infections get in the way of work. All 33 patients affected by allergies at work reported increased productivity since the initiation of immunotherapy. Allergy symptoms had been the most common reason for decreased productivity, followed by infections. Additionally, 12 patients stated that side effects from prior allergy medications had made them less productive. Allergy injections allowed them to discontinue the medications, and they were now more productive. Thirty-one people had missed work days as a consequence of allergy symptoms or infections. Before the initiation of immunotherapy, 29 of the 31 patients missed somewhere between one and six work days within a six-month period. The other two patients stated that they missed up to 12-18 work days within a six-month period. Including a1l31 patients, an average of4,2 more work days were missed every six months prior to initiation of immunotherapy. If the two "extreme" patients are not included, the difference is 3.2 days.
Thirty-eight patients, prior to beginning allergy injections, were making frequent visits to their physicians for -----"----------~~~~--Why compromise...
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QUALITY OF LIFE ANALYSIS OF PATIENTS UNDERGOING IMMUNOTHERAPY FOR ALLERGIC RHINITIS fewer than three antibiotic courses per year, tending to just tolerate the infections and let them resolve spontaneously. This left 36 people taking three or more courses of antibiotics per year. Thirty-two of these 36 (89%) were able to decrease their antibiotic use by 50% or more since immunotherapy was initiated.
The most impressive finding in this study was the response when people were asked whetherthey felt that allergy immunotherapy was a worthwhile investment of their time and money. Immunotherapy can be a time-consuming undertaking and creates additional expense for patients. Despite this, 55 of the 60 adults (92%) felt that immunotherapy was worthwhile. We asked the patients to estimate how many months of treatment had passed before they had noted some benefit and, excluding one patient who reported 24 months, the average amount of time was 4.2 months.
Discussion
Allergic rhinitis, while nota life-threatening problem, does provide the potential for significant morbidity. Symptoms and their effect on functional status are major concerns of many patients. Additionally, those affected often experience infectious complications. Patients are generally very grateful for anything that provides relief. Unfortunately, even with all the medicines available, many do not get adequate relief. In this study, it is evident that most of the patients in this group are pleased with the results of immunotherapy.
Considering the RAST scores in our patients, it is interesting to note the lack of correlation between RAST levels and the severity of patient symptomatology. Patients with levels of 0/1 or I were just as symptomatic as those with levels as high as 4 and 5. Additionally, all patients, at any level of sensitivity, received benefit from immunotherapy. Thus, it is obvious to us that as long as the RAST scores are positive or even borderline, the decision to utilize immunotherapy should not be based on RAST or SET levels: IJ it should be based on the significance of symptomatology (and its correlation with antigen exposure) and lack of improvement with first-line therapies. It is accepted that there is no correlation between endpoint or RAST class and symptoms.
Twenty-five of the patients involved in this study had previously received allergy injections elsewhere. Fifteen felt they did not benefit from the prior injections, yet did benefit from the immunotherapy program utilized in our department. This finding tends to support the effectiveness of this method of immunotherapy. Seven patients had received benefit from their prior immunotherapy, while three patients perceived no benefit from either the current or past allergy injections.
In Vitro Allergy Testing for Effective Asthma Outcomes
The worldwide incidence of asthma is rising. Several clinical outcomes studies have shown that early detection of the allergic 'trigger' and subsequent management of the asthmatic patient by a physician trained in allergy, greatly reduce the frequency of emergency room visits.
Identifying the trigger early in the disease state is the most important aspect of reducing the costs associated with asthma and improving the patient's quality of life.
Traditionally, allergists have concentrated their efforts in identifying the allergic triggers using various methods of skin testing. Today, a physician can choose to reduce the discomfort of the patient. By drawing a single tube of blood, the physician can identify the environmental IgE mediated offenders using the in vitro test. RAST has advanced in reliability to now be listed as an alternative to skin testing in the National Asthma Education and Prevention Program's Guidelines for the Diagnosis and Management ofAsthma.
As a laboratory director in today's outcomesbased medicine, your focus on developing a cost-effective disease state testing algorithm may lead you to the in vitro allergy test. One other important point to raise is the need for surgery in some of these patients. Eleven of our patients had undergone septoplasty, turbinoplasty and/or endoscopic sinus surgery during the course of immunotherapy. While immunotherapy was beneficial in all ofthese patients, they all derived additional benefit from their surgical procedures. This underscores immunotherapy's inability to correct structural problems. Surgical procedures may be necessary to give the patient maximum benefit.
Six: of the patients complained of significant balance disturbances and dizziness prior to beginning immunotherapy. All six had nasal symptoms as well. In addition to helping with theirnasal symptoms, all six reported significant relief of their balance disturbance since beginning immunotherapy. Three of the patients stated that the balance disturbance had been a more significant problem than their nasal symptoms or infections, and all three reported previous severe balance disturbances that had decreased to only mild problems since allergy injections were initiated. One patient had presumed bilateral Meniere's disease. He had undergone a previous right translabyrinthine vestibular nerve section and one year later developed contralateral Meniere's disease. Eighteen months into immunotherapy the patient's hearing loss and vertigo have stabilized. These experiences at our institution have led us to consider allergy screening in all patients with balance disturbances and a work-up that does not indicate another etiology.
Only four of our patients had a history of asthma. All four complained of moderate to severe asthma prior to immunotherapy. Two patients noted complete relief of their asthma and were able to discontinue asthma medications after starting immunotherapy. The other two patients noted some improvement but still required the use of medications for asthma. Obviously, with only four patients we are unable to make a statement regarding the effects of immunotherapy on asthma.
In reference to the five patients who felt immunotherapy had not been a worthwhile investment for them, one of these patient's main problems was a balance disturbance. While he felt that he did not receive benefit from immunotherapy from this standpoint, he did report some relief of his nasal symptoms. Two of the patients had continuing severe local reactions to the allergy injections, making dosage advancement very difficult. Because of this, the doses they are currently receiving have not provided significant symptomatic relief. The remaining two patients stated that they had some slight improvement in symptoms, but were expecting much more. As a result, they felt immunotherapy, with all the expense and time involved, had not been worthwhile.
Despite the time and effort involved in allergy immunotherapy, perhaps one reason that our patients accepted it so well is our home injection therapy program. When patients have been on immunotherapy long enough to achieve a maintenance level, if they wish they are allowed to begin 536 therapy outside our office. Patients are carefully instructed about the necessary safety precautions and how to administer their own injections at home. All are provided with injectable epinephrine and instructions on managing a reaction. Patients still on weekly injections are given four single-dose vials, one for each week, at their current dosage. In this situation, each dose is the same and they are not advanced during the home therapy. When the patients are on maintenance dosages every other week, they only need to return every two months for new vials. Further dosage advancement, if necessary, is carried out by administering the first injection in the office followed by single-dose vials at the same dosage level for home administration. Currently, there have not been any complications as a result of home injection therapy. This is in accord with data currently being collected by the American Academy of Otolaryngic Allergy (AAOA) on out-of-office immunotherapy.
Summary
We acknowledge the limitations of this study. It is not a prospective study with controls and is instead retrospective. However, we believe our data demonstrate the effectiveness of immunotherapy for allergic rhinitis based on quantitative testing as measured by a very practical tool: the benefits evident to the patient. This is the first study that documents these benefits with a quality of life questionnaire. A true multi-dimensional, prospective, controlled study is still necessary to provide a cost-benefit analysis.
